Clinical Trials Logo

Filter by:
NCT ID: NCT02155647 Completed - Clinical trials for Carcinoma, Merkel Cell

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Start date: July 3, 2014
Phase: Phase 2
Study type: Interventional

This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).

NCT ID: NCT02154217 Completed - Glaucoma Clinical Trials

Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a data revision with a focus on 24 hour perfusion pressures of data from a previous randomized, double masked, multicenter clinical trial. The aim was to compare the effect of bimatoprost and the fixed combination of latanoprost and timolol (LTFC) on 24-hour mean intraocular pressure (IOP) after patients are switched from a nonfixed combination of latanoprost and timolol. The main findings of the original trial had been published on Ophthalmology [2007;114: 2244-2251].

NCT ID: NCT02153801 Completed - Clinical trials for Genito Urinary Function Evaluation

Genito Urinary Function With High or Low Inferior Mesenteric Artery Ligation in Laparoscopic Anterior Rectal Resection

Start date: September 2014
Phase: N/A
Study type: Interventional

The aim of this study is to compare the incidence of genito-urinary function depression and anastomotic leak in Laparoscopic Anterior Rectal Resection (LAR) with Total Mesorectal Excision with Ligation if the Inferior Mesenteric Artery at the origin or preserving the Left Colic Artery by a prospective randomized trial.

NCT ID: NCT02153190 Completed - Clinical trials for Type 1 Diabetes Mellitus

Hybrid Artificial Pancreas in Home Setting

AP Hybrid
Start date: May 2014
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is the evaluate an Artificial Pancreas during 2 months in home setting in Type 1 Diabetic patients

NCT ID: NCT02152371 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

AWARD-9
Start date: May 2014
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.

NCT ID: NCT02151929 Completed - Clinical trials for ST Elevation Acute Myocardial Infarction

Bioresorbable Vascular Scaffold in Patients With Myocardial Infarction

Start date: May 2013
Phase: Phase 4
Study type: Interventional

Evaluation of the feasibility and safety of Bioresorbable Vascular Scaffold (BVS) in patient treated with primary PCI (pPCI).

NCT ID: NCT02151682 Completed - Pain Clinical Trials

A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain

Start date: April 29, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Tapentadol has already been studied in adults. This study is needed to find out if tapentadol works and is safe to use in children and adolescents with long-term pain.

NCT ID: NCT02150603 Completed - Clinical trials for Heart Defects, Congenital

Patient-Reported Outcomes in Adults With Congenital Heart Disease

APPROACH-IS
Start date: April 2013
Phase: N/A
Study type: Observational

The purpose of this study is to examine the differences in perceived health, psychosocial functioning, behavioral outcomes and quality of life of adults with congenital heart disease who are living in different areas of the world, and how these differences can be understood (e.g., differences in sense of coherence or illness perceptions).

NCT ID: NCT02150356 Completed - Clinical trials for Incretin Hormones Plasma Levels

Effects of Aleurone-enriched Products on Cardiovascular Risk Factors

Start date: January 2014
Phase: N/A
Study type: Interventional

Very few studies have evaluated the effect of aleurone-enriched grains on cardiovascular risk factors. Price et al.(2010) have shown that 4-week supplementation of aleurone-enriched products (27 g/day of aleurone) increased betaine concentration in plasma whereas reduced homocysteine and LDL-cholesterol levels. Interestingly, aleurone had no effect on total antioxidant status or endothelial function, whereas an improvement of C-reactive protein was observed (Price RK et al, 2012). It is not known whether consumption of more than 27g/day of aleurone-enriched products with higher ferulic acid biodisponibility and longer time of treatment could influence these parameters in individuals with metabolic syndrome. Noteworthy, no studies have investigated the effect of aleurone-enriched products on fasting and postprandial glycemic homeostasis and lipid metabolism. In addition, mechanisms by which aleurone may act in vivo are still unknown. The aim of this study is to investigate whether 8 weeks supplementation with aleurone-enriched products may influence glucose and lipid metabolism, incretin hormones levels, satiety, inflammation, oxidative stress and endothelial function in overweight/obese subjects with high cardiovascular risk.

NCT ID: NCT02150343 Completed - Rhinoconjunctivitis Clinical Trials

Phase II HDM-SPIRE Safety and Efficacy Study

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, Quality of Life and Sleep Quality